Literature DB >> 10428853

Tissue-specific regulation of the ecto-5'-nucleotidase promoter. Role of the camp response element site in mediating repression by the upstream regulatory region.

J Spychala1, A G Zimmermann, B S Mitchell.   

Abstract

We have isolated the 5' region of the ecto-5'-nucleotidase (low K(m) 5'-NT) gene and established that a 969-base pair (bp) fragment confers cell-specific expression of a CAT reporter gene that correlates with the expression of endogenous ecto-5'-NT mRNA and enzymatic activity. A 768-bp upstream negative regulatory region has been identified that conferred lymphocyte-specific negative regulation in a heterologous system with a 244-bp deoxycytidine kinase core promoter. DNase I footprinting identified several protected areas including Sp1, Sp1/AP-2, and cAMP response element (CRE) binding sites within the 201-bp core promoter region and Sp1, NRE-2a, TCF-1/LEF-1, and Sp1/NF-AT binding sites in the upstream regulatory region. Whereas the CRE site was essential in mediating the negative activity of the upstream regulatory region in Jurkat but not in HeLa cells, mutation of the Sp1/AP-2 site decreased promoter activity in both cell lines. Electrophoretic mobility shift assay analysis of proteins binding to the CRE site identified both ATF-1 and ATF-2 in Jurkat cells. Finally, phorbol 12-myristate 13-acetate increased the activity of both the core and the 969-bp promoter fragments, and this increase was abrogated by mutations at the CRE site. In summary, we have identified a tissue-specific regulatory region 5' of the ecto-5'-NT core promoter that requires the presence of a functional CRE site within the basal promoter for its suppressive activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428853     DOI: 10.1074/jbc.274.32.22705

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Regulation of Expression of Hyperalgesic Priming by Estrogen Receptor α in the Rat.

Authors:  Luiz F Ferrari; Dionéia Araldi; Jon D Levine
Journal:  J Pain       Date:  2017-01-09       Impact factor: 5.820

2.  Developmental increase in ecto-5'-nucleotidase activity overlaps with appearance of two immunologically distinct enzyme isoforms in rat hippocampal synaptic plasma membranes.

Authors:  Ivana Grkovic; Ivana Bjelobaba; Nadezda Nedeljkovic; Natasa Mitrovic; Dunja Drakulic; Milos Stanojlovic; Anica Horvat
Journal:  J Mol Neurosci       Date:  2014-02-22       Impact factor: 3.444

3.  Ecto-5'-nucleotidase expression is associated with the progression of renal cell carcinoma.

Authors:  Y I Yu; Wei Wang; Lei Song; Wentao Hu; Chi Dong; Hailong Pei; Guangming Zhou; Zhongjin Yue
Journal:  Oncol Lett       Date:  2015-04-23       Impact factor: 2.967

4.  Activity and expression of ecto-5'-nucleotidase/CD73 are increased by thyroid hormones in vascular smooth muscle cells.

Authors:  Alessandra S K Tamajusuku; Maria Alicia Carrillo-Sepúlveda; Elizandra Braganhol; Márcia R Wink; João J F Sarkis; Maria Luiza M Barreto-Chaves; Ana Maria O Battastini
Journal:  Mol Cell Biochem       Date:  2006-05-23       Impact factor: 3.396

5.  Extracellular ATP Selectively Upregulates Ecto-Nucleoside Triphosphate Diphosphohydrolase 2 and Ecto-5'-Nucleotidase by Rat Cortical Astrocytes In Vitro.

Authors:  Dusica Brisevac; Marija Adzic; Danijela Laketa; Ana Parabucki; Milena Milosevic; Irena Lavrnja; Ivana Bjelobaba; Jean Sévigny; Markus Kipp; Nadezda Nedeljkovic
Journal:  J Mol Neurosci       Date:  2015-06-17       Impact factor: 3.444

6.  Thyroid hormone stimulates 5'-ecto-nucleotidase of neonatal rat ventricular myocytes.

Authors:  Marcela Sorelli Carneiro-Ramos; Vanessa Beatriz da Silva; Marconi Barbosa Coutinho; Ana Maria Oliveira Battastini; João José Freitas Sarkis; Maria Luiza M Barreto-Chaves
Journal:  Mol Cell Biochem       Date:  2004-10       Impact factor: 3.396

7.  CD73: an emerging checkpoint for cancer immunotherapy.

Authors:  Siqi Chen; Derek A Wainwright; Jennifer D Wu; Yong Wan; Daniela E Matei; Yi Zhang; Bin Zhang
Journal:  Immunotherapy       Date:  2019-06-21       Impact factor: 4.196

Review 8.  Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.

Authors:  Selena Vigano; Dimitrios Alatzoglou; Melita Irving; Christine Ménétrier-Caux; Christophe Caux; Pedro Romero; George Coukos
Journal:  Front Immunol       Date:  2019-06-06       Impact factor: 7.561

Review 9.  CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth.

Authors:  Bertrand Allard; Martin Turcotte; John Stagg
Journal:  J Biomed Biotechnol       Date:  2012-10-16

10.  Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes.

Authors:  Mikkel G Terp; Odd L Gammelgaard; Henriette Vever; Morten F Gjerstorff; Henrik J Ditzel
Journal:  Mol Oncol       Date:  2021-07-16       Impact factor: 6.603

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.